More than 82 million people could be living with dementia by 2030,1 the majority in low-income and middle-income countries where access to specialist care and diagnostic tests is highly variable.

Discover the latest non-invasive Alzheimer’s detection breakthroughs, from AI and heart rate tracking to digital twins and sensor tests.

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

It promises the benefits of a 10,000-step walk in just 30 minutes. No gym membership required. Just a pair of shoes and a ...

New drugs show promise, and research finds value in vaccines, antivirals, exercise and probiotics.

One-third of people older than 85 in the United States are estimated to live with Alzheimer's disease today, according to the ...

Regina Barber and Rachel Carlson of Short Wave talk about endangered eagles in Japan, the lifestyles of deep-living ocean ...

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...

This research offers hope. By finding brain diseases earlier, we might be able to slow them down or manage them better. If ...

SNAP participants showed a slower decline in cognitive function over 10 years, essentially maintaining up to three additional ...

Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read more here.

The Nebraska sales proceeds from ‘A Life Well Fed’ will go toward the Nebraska Alzheimer’s Association to provide help for families who have been or will one day be in similar scenarios.